Targeting p75NTR, NGF, and NOTCH Signaling: Network Pharmacology Insights into Neurodegenerative and Mental Health Therapies from Salinispora and Streptomyces Actinobacteria
DOI:
https://doi.org/10.64229/56wgm318Keywords:
Network pharmacology, Neurodegeneration, Drug discoveryAbstract
Marine Actinobacteria, notably Salinispora and Streptomyces species, are emerging as promising sources of bioactive compounds with therapeutic potential for neurodegenerative and mental health disorders. This study employs a network pharmacology approach to investigate how compounds from these marine microbes interact with key genes in the p75 Neurotrophin receptor (p75NTR), nerve growth factor (NGF), and NOTCH signaling pathways, all of which are crucial in neurodegenerative processes. A comprehensive screening pipeline, involving absorption, distribution, metabolism, and excretion (ADME) evaluation (drug-likeness, oral bioavailability, blood-brain barrier permeability) and in silico toxicity profiling across five major toxicity categories, was conducted to identify bioactive compounds with favorable pharmacokinetic properties and non-toxic profiles. Top candidates were selected based on their significant interactions with genes related to the aforementioned signaling pathways. Notably, Salinosporamide A (NPI-0052 and its fused-lactam-lactone form) from Salinispora, and Bonactin, Azamerone, and Methoxyneihumicin from Streptomyces, were identified as key compounds. These showed interactions with genes such as MAPK1, NCSTN, APH1A, AR, JAK2, and PSENEN, which are crucial in regulating p75NTR-mediated, NGF, and NOTCH signaling. The p75NTR pathway is involved in neuronal survival, apoptosis, and synaptic function; its disruption contributes to neurodegeneration. NGF signaling supports neuronal differentiation and survival, with its dysregulation linked to Alzheimer's and similar diseases. The NOTCH pathway governs neurodevelopment, cell communication, and synaptic plasticity, with perturbations associated with schizophrenia and neurodegenerative disorders.
References
[1]Grezenko H, Rodoshi ZN, Mimms CS, Ahmed M, Sabani A, Hlaing MS, et al. From Alzheimer’s disease to anxiety, epilepsy to schizophrenia: A comprehensive dive into neuro-psychiatric disorders. Cureus, 2024, 16(4), e58776. DOI: 10.7759/cureus.58776
[2]Hong H, Kim BS, Im HI. Pathophysiological role of neuroinflammation in neurodegenerative diseases and psychiatric disorders. International Neurourology Journal, 2016, 20(Suppl 1), S2-S7. DOI: 10.5213/inj.1632604.302
[3]Guzman-Martinez L, Maccioni RB, Andrade V, Navarrete LP, Pastor MG, Ramos-Escobar N. Neuroinflammation as a common feature of neurodegenerative disorders. Frontiers in Pharmacology, 2019, 10, 1008. DOI: 10.3389/fphar.2019.01008
[4]Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A review of the common neurodegenerative disorders: Current therapeutic approaches and the potential role of nanotherapeutics. International Journal of Molecular Sciences, 2022, 23(3), 1851. DOI: 10.3390/ijms23031851
[5]Jourdi G, Fleury S, Boukhatem I, Lordkipanidzé M. Soluble p75 neurotrophic receptor as a reliable biomarker in neurodegenerative diseases: What is the evidence? Neural Regeneration Research, 2024, 19(3), 536-541. DOI: 10.4103/1673-5374.380873
[6]Joshi R, Salton SRJ. Neurotrophin crosstalk in the etiology and treatment of neuropsychiatric and neurodegenerative disease. Frontiers in Molecular Neuroscience, 2022, 15, 932497. DOI: 10.3389/fnmol.2022.932497
[7]Ho DM, Artavanis-Tsakonas S, Louvi A. The Notch pathway in CNS homeostasis and neurodegeneration. WIREs Developmental Biology, 2019, 9(1), e358. DOI: 10.1002/wdev.358
[8]Rad SK, Arya A, Karimian H, Madhavan P, Rizwan F, Koshy S, et al. Mechanism involved in insulin resistance via accumulation of β-amyloid and neurofibrillary tangles: Link between type 2 diabetes and Alzheimer’s disease. Drug Design, Development and Therapy, 2018, 12, 3999-4021. DOI: 10.2147/DDDT.S173970
[9]Wang X, Feng S, Deng Q, Wu C, Duan R, Yang L. The role of estrogen in Alzheimer’s disease pathogenesis and therapeutic potential in women. Molecular and Cellular Biochemistry, 2025, 480(4), 1983-1998. DOI: 10.1007/s11010-024-05071-4
[10]Chowdhury MR, Kumar V, Deepa VS. Unraveling metabolic pathways and key genes in Alzheimer’s, type 2 diabetes, and estrogen dysregulation among aging women: a systems biology approach. Journal of Proteins and Proteomics, 2024, 15(3): 347-360. DOI: 10.1007/s42485-024-00157-5
[11]Fraile-Martinez O, Alvarez-Mon MA, Garcia-Montero C, Pekarek L, Guijarro LG, Lahera G, et al. Understanding the basis of major depressive disorder in oncological patients: Biological links, clinical management, challenges, and lifestyle medicine. Frontiers in Oncology, 2022, 12, 956923. DOI: 10.3389/fonc.2022.956923
[12]Chowdhury MR, Tiwari A, Karamveer K, Dubey GP, Tiwary BK, Deepa VS. Clinical application and pharmacological mechanism of polyherbal phytoformulations in breast cancer and depression treatment: Review and network pharmacological analysis. Proceedings of the Indian National Science Academy, 2023, 89(3), 560-583. DOI: 10.1007/s43538-023-00193-7
[13]Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nature Reviews Neurology, 2018, 14(7), 399-415. DOI: 10.1038/s41582-018-0013-z
[14]Makhoba XH, Viegas C Jr, Mosa RA, Viegas FPD, Pooe OJ. Potential impact of the multi-target drug approach in the treatment of some complex diseases. Drug Design, Development and Therapy, 2020, 14, 3235-3249. DOI: 10.2147/DDDT.S257494
[15]Akhtar A, Andleeb A, Waris TS, Bazzar M, Moradi AR, Awan NR, et al. Neurodegenerative diseases and effective drug delivery: A review of challenges and novel therapeutics. Journal of Controlled Release, 2021, 330, 1152-1167. DOI: 10.1016/j.jconrel.2020.11.021
[16]Mohd Sairazi NS, Sirajudeen KNS. Natural products and their bioactive compounds: Neuroprotective potentials against neurodegenerative diseases. Evidence-Based Complementary and Alternative Medicine, 2020, 2020, 6565396. DOI: 10.1155/2020/6565396
[17]Chowdhury MR, Reddy RVS, Nampoothiri NK, Erva RR, Vijaykumar SD. Exploring bioactive natural products for treating neurodegenerative diseases: A computational network medicine approach targeting the estrogen signaling pathway in amyotrophic lateral sclerosis and Parkinson's disease. Metabolic Brain Disease, 2025, 40(4), 169. DOI: 10.1007/s11011-025-01585-y
[18]Silva M, Seijas P, Otero P. Exploitation of marine molecules to manage Alzheimer's disease. Marine Drugs, 2021, 19(7), 373. DOI: 10.3390/md19070373
[19]Liu Z, Sun W, Hu Z, Wang W, Zhang H. Marine Streptomyces-derived novel alkaloids discovered in the past decade. Marine Drugs, 2024, 22(1), 51. DOI: 10.3390/md22010051
[20]Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W. Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinispora. Angewandte Chemie International Edition, 2023, 42(3), 355-357. DOI: 10.1002/anie.200390115
[21]Prudhomme J, McDaniel E, Ponts N, Bertani S, Fenical W, Jensen P, et al. Marine actinomycetes: A new source of compounds against the human malaria parasite. PLoS ONE, 2008, 3(6), e2335. DOI: 10.1371/journal.pone.0002335
[22]Chowdhury MR, Kizhakedathil MPJ, Kumar V, Saktheeswaran M, Mathesh KK, Deepa VS. Exploring the therapeutic potential of marine actinomycetes: A systems biology-based approach for Alzheimer’s disease treatment. Discover Molecules, 2024, 1(1), 4. DOI: 10.1007/s44345-024-00004-6
[23]Chowdhury MR, Karamveer K, Tiwary BK, Nampoothiri NK, Erva RR, Deepa VS. Integrated systems pharmacology, molecular docking, and MD simulations investigation elucidating the therapeutic mechanisms of BHD in Alzheimer’s disease treatment. Metabolic Brain Disease, 2024, 40 (1), 8. DOI: 10.1007/s11011-024-01460-2
[24]Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness, and medicinal chemistry friendliness of small molecules. Scientific Reports, 2017, 7, 42717. DOI: 10.1038/srep42717
[25]Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Research, 2018, 46(W1), W257-W263. DOI: 10.1093/nar/gky318
[26]Daina A, Michielin O, Zoete V. SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Research, 2019, 47(W1): W357-W364. DOI: 10.1093/nar/gkz382
[27]Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Research, 2007, 35(Database issue), D198-D201. DOI: 10.1093/nar/gkl999
[28]Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, Ronzano F, Centeno E, Sanz F, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Research, 2020, 48(D1), D845-D855. DOI: 10.1093/nar/gkz1021
[29]Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Research, 2021, 49(D1), D605-D612. DOI: 10.1093/nar/gkaa1074
[30]Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Research, 2003, 13(11), 2498-2504. DOI :10.1101/gr.1239303
[31]Chowdhury MR, Vijaykumar SD. A systems biology approach reveals dual neurotherapeutic mechanisms of Dioscorea bulbifera in Alzheimer’s disease via estrogen signaling and cholinergic modulation. Inflammopharmacology, 2025, 33(9):5483-5508. DOI: 10.1007/s10787-025-01872-1
[32]Fonseka P, Pathan M, Chitti SV, Kang T, Mathivanan S. FunRich enables enrichment analysis of OMICs datasets. Journal of Molecular Biology, 2021, 433(11), 166747. DOI: 10.1016/j.jmb.2020.166747
[33]Jayaprakashvel M. Therapeutically active biomolecules from marine actinomycetes. Journal of Modern Biotechnology, 2012, 1(1), 1-7.
[34]Cho JY, Kwon HC, Williams PG, Jensen PR, Fenical W. Azamerone, a terpenoid phthalazinone from a marine-derived bacterium related to the genus Streptomyces (Actinomycetales). Organic Letters, 2006, 8(12), 2471-2474. DOI: 10.1021/ol060630r
[35]Liu R, Zhu T, Li D, Gu J, Xia W, Fang Y, et al. Two indolocarbazole alkaloids with apoptosis activity from a marine-derived Actinomycete Z(2)039-2. Archives of Pharmacal Research, 2007, 30(3), 270-274. DOI: 10.1007/BF02977605
[36]Jeong SY, Shin HJ, Kim TS, Lee HS, Park SK, Kim HM. Streptokordin, a new cytotoxic compound of the methylpyridine class from a marine-derived Streptomyces sp. KORDI-3238. The Journal of Antibiotics, 2006, 59(4), 234-240. DOI: 10.1038/ja.2006.33
[37]Fukuda T, Yamada Y, Komatsu K, Ichikawa N. Isomethoxyneihumicin, a new cytotoxic agent produced by marine Nocardiopsis alba KM6-1. The Journal of Antibiotics, 2017, 70(5), 590-594. DOI: 10.1038/ja.2016.152
[38]Wang P, Xi L, Liu P, Wang Y, Wang W, Huang Y, et al. Diketopiperazine derivatives from the marine-derived actinomycete Streptomyces sp. FXJ7.328. Marine Drugs, 2013, 11(4), 1035-1049. DOI: 10.3390/md11041035
[39]De Rop AS, Rombaut J, Willems T, De Graeve M, Vanhaecke L, Hulpiau P, et al. Novel alkaloids from marine actinobacteria: Discovery and characterization. Marine Drugs, 2021, 20(1), 6. DOI: 10.3390/md20010006
[40]Yang XW, Peng K, Liu Z, Zhang GY, Li J, Wang N, et al. Strepsesquitriol, a rearranged zizaane-type sesquiterpenoid from the deep-sea-derived actinomycete Streptomyces sp. SCSIO 10355. Journal of Natural Products, 2013, 76(12), 2360-2363. DOI: 10.1021/np400923c
[41]Ding T, Yang LJ, Zhang WD, Shen YH. The secondary metabolites of rare actinomycetes: Chemistry and bioactivity. RSC Advances, 2019, 9(38), 21964-21988. DOI: 10.1039/c9ra03579f
[42]Sivalingam P, Hong K, Pote J, Prabakar K. Extreme environment Streptomyces: Potential sources for new antibacterial and anticancer drug leads? International Journal of Microbiology, 2019, 2019, 5283948. DOI: 10.1155/2019/5283948
[43]Shu YH, Lu XM, Wei JX, Xiao L, Wang YT. Update on the role of p75NTR in neurological disorders: A novel therapeutic target. Biomedicine & Pharmacotherapy, 2015, 76, 17-23. DOI: 10.1016/j.biopha.2015.10.010
[44]Lasky JL, Wu H. Notch signaling, brain development, and human disease. Pediatric Research, 2005, 57(5), 104R-109R. DOI: 10.1203/01.PDR.0000159632.70510.3D
[45]Rahman MH, Bajgai J, Fadriquela A, Sharma S, Trinh TT, Akter R, et al. Therapeutic potential of natural products in treating neurodegenerative disorders and their future prospects and challenges. Molecules, 2021, 26(17), 5327. DOI: 10.3390/molecules26175327
[46]Patne AY, Akramuddaula K, Patel D, Suryawanshi M, Vinchurkar K. Applications of natural polymers in controlled-release systems. Innovative Pharmaceutical Excipients: Natural Sources. Singapore: Springer Nature Singapore, 2025, 249-298. DOI: 10.1007/978-981-96-7959-1_11
[47]Torres J, Costa I, Peixoto AF, Silva R, Sousa Lobo JM, Silva AC. Intranasal lipid nanoparticles containing bioactive compounds obtained from marine sources to manage neurodegenerative diseases. Pharmaceuticals, 2023, 16(2), 311. DOI: 10.3390/ph16020311
Published
Issue
Section
License
Copyright (c) 2026 Mayank Roy Chowdhury, Sudarshana Deepa Vijaykumar (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
